Treatment of heart failure with growth hormone
US6306826A · kind A · utility
2Cited by
5References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 4, 1997 |
| Grant date | Oct 23, 2001 |
| Priority date | — |
| Expiry date | Jun 4, 2017 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P9/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Heart failure following myocardial infarction is treated by administration of an angiotensin II inhibitor for 8-12 weeks, followed by administration of a growth hormone for 1-3 weeks.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.